Denali Therapeutics (NasdaqGS:DNLI) FY Conference January 13, 2026 04:30 PM ET Company ParticipantsNone - Company RepresentativeAlex Schuth - Chief Operating and Financial OfficerRyan Watts - CEOPeter Chin - Acting Chief Medical Officer and Head of DevelopmentConference Call ParticipantsJess Fye - Biotech AnalystNone - AnalystJess FyeGreat. Welcome, everyone. Good afternoon. My name's Jess Fye. I'm a biotech analyst at JPMorgan, and we're continuing our 44th Annual Healthcare Conference today with Denali. F ...

Core Insights - Denali is at a pivotal moment in the development of new medicines aimed at crossing the blood-brain barrier and addressing degeneration [3][4] Company Overview - Denali has been working on innovative transport vehicle technology for over two decades, focusing on the blood-brain barrier and tissue distribution [3] - The company aims to utilize transferrin receptor and other receptors to create a new class of medicines that can effectively deliver treatments to the brain, muscle, and bone [3] Future Milestones - Denali is expected to achieve significant milestones in the next 12 to 24 months, although specific details on these milestones were not provided in the discussion [2]